期刊
BRIEFINGS IN BIOINFORMATICS
卷 19, 期 4, 页码 656-678出版社
OXFORD UNIV PRESS
DOI: 10.1093/bib/bbw136
关键词
precision medicine; drug repositioning; translational bioinformatics; drug development; drug discovery; precision pharmacology; systems pharmacology
资金
- National Institutes of Health: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK098242-03]
- National Cancer Institute (NCI) [U54-CA189201-02]
- Illuminating the Druggable Genome (IDG)
- Knowledge Management Center - NIH Common Fund
- National Center for Advancing Translational Sciences (NCATS) [UL1TR000067]
- Clinical and Translational Science Awards (CTSA) grant
Increase in global population and growing disease burden due to the emergence of infectious diseases (Zika virus), multidrug-resistant pathogens, drug-resistant cancers (cisplatin-resistant ovarian cancer) and chronic diseases (arterial hypertension) necessitate effective therapies to improve health outcomes. However, the rapid increase in drug development cost demands innovative and sustainable drug discovery approaches. Drug repositioning, the discovery of new or improved therapies by reevaluation of approved or investigational compounds, solves a significant gap in the public health setting and improves the productivity of drug development. As the number of drug repurposing investigations increases, a new opportunity has emerged to understand factors driving drug repositioning through systematic analyses of drugs, drug targets and associated disease indications. However, such analyses have so far been hampered by the lack of a centralized knowledgebase, benchmarking data sets and reporting standards. To address these knowledge and clinical needs, here, we present RepurposeDB, a collection of repurposed drugs, drug targets and diseases, which was assembled, indexed and annotated from public data. RepurposeDB combines information on 253 drugs [small molecules (74.30%) and protein drugs 25.29%)] and 1125 diseases. Using RepurposeDB data, we identified pharmacological (chemical descriptors, physicochemical features and absorption, distribution, metabolism, excretion and toxicity properties), biological (protein domains, functional process, molecular mechanisms and pathway cross talks) and epidemiological (shared genetic architectures, disease comorbidities and clinical phenotype similarities) factors mediating drug repositioning. Collectively, RepurposeDB is developed as the reference database for drug repositioning investigations. The pharmacological, biological and epidemiological principles of drug repositioning identified from the meta-analyses could augment therapeutic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据